These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Depo Provera. Position paper on clinical use, effectiveness and side effects. Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M. Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658 [Abstract] [Full Text] [Related]
3. Injectable contraceptives: safe and effective. IPPF Med Bull; 1982 Feb; 16(1):3-4. PubMed ID: 12264296 [Abstract] [Full Text] [Related]
13. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. Draper BH, Morroni C, Hoffman M, Smit J, Beksinska M, Hapgood J, Van der Merwe L. Cochrane Database Syst Rev; 2006 Jul 19; 2006(3):CD005214. PubMed ID: 16856087 [Abstract] [Full Text] [Related]
14. Vaginal bleeding disturbances associated with the discontinuation of long-acting injectable contraceptives. From the World Health Organization Special Programme for Research, Development, and Research Training in Human Reproduction; Task Force on Long-acting Systemic Agents for the Regulation of Fertility. Gray RH, Parker RA, Diethelm P. Br J Obstet Gynaecol; 1981 Mar 19; 88(3):317-21. PubMed ID: 7008825 [Abstract] [Full Text] [Related]
19. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues? Rosenfield A, Maine D, Rochat R, Shelton J, Hatcher RA. JAMA; 1983 Jun 03; 249(21):2922-8. PubMed ID: 6221125 [Abstract] [Full Text] [Related]